Clinical Trial of the Inactivated Influenza Vaccine (0.25ml Formulation for Pediatric Use)

Study Overview
=================
Brief Summary
-----------------
The clinical trial was designed to evaluate the immunogenicity and safety against pediatric Inactivated influenza vaccine (Split Virion) (0.25ml formulation) of Hualan administered on infants age 6 months to 36 months.

Detailed Description
-----------------
The clinical trial was designed randomized and double-blind. Participants included up to 810 persons (540 persons in test group and 270 persons in control group). Healthy 6-36 months infants were selected, whose guardians were volunteers and had signed the informed consent. Subjects were selected according to the inclusion and exclusion criteria. Every subject accepted 30min's observation in the hospital after vaccination and received periodic follow-up till the fourth week after the boost vaccination. Blood of subjects was collected at the third week after the boost vaccination for the analysis of the immunogenicity. During the test, the adverse reactions and detailed information were reported to the SFDA under the status of blinding every month. Unblinding was conducted after the completion of the follow-up of subjects.

Official Title
-----------------
A Double - Blind, Randomized, - Controlled Clinical Trial With Inactivated Influenza Vaccine (Split Virion)(0.25ml Formulation for Pediatric Use)

Conditions
-----------------
Influenza

Intervention / Treatment
-----------------
* Biological: Influenza Split Vaccine
* Biological: Inactivated Influenza Vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infants aging 6-36 months, their guardians understand and sign the informed consent Healthy infant by inquiring illness history, physical examination and clinical judgment and who complies with vaccination of this product Be able to comply with the requirement of clinical trial protocol Have no history of vaccination within the past 6 months and vaccination with other product within the latest 1 week Axillary temperature ≤37.0℃. Exclusion Criteria: Exclusion criteria for primary vaccination: History of other vaccine or immunoglobulin inoculation within 2 weeks History of eclampsia, epilepsy, encephalopathy and mental disease or family disease History of vaccination allergy or allergy to drug and food (egg) Known or suspected immunological function defects, including immunosuppressant therapy (radiotherapy, chemotherapy, corticosteroid hormone, antimetabolites, cytotoxic drug), genetic defects (favism), HIV infection or other reasons Congenital malformation, maldevelopment or serious chronic disease (such as Down syndrome, diabetes, sickle cell anemia or neurologic disease) Acute and chronic contagion, active infection (history of fever within the past 3 days (axillary temperature ≥38.0℃) or acute disease needing application of antibiotics or anti-virus treatment in the whole body) Organic diseases such as liver, kidney, serious cardiovascular disease Malignancy (tumor), serious asthma Thrombopenia or other coagulopathy that may cause contraindication of intramuscular injection Any condition resulting in the absence or removal the spleen Hypertension (not including the higher blood pressure below 150mmHg and lower blood pressure below 100mmHg controlled by drug) Participating in another clinical trial or any condition that, in the judgment of investigator, may affect trial assessment. Exclusion criteria for a boost vaccination: Any condition in the Exclusion criteria of the first injection after inclusion Adverse reactions level 3 or above within 72 hours after first vaccination; Serious adverse reactions having casual relationship with the first inoculation of test vaccine Subjects are not willing to be inoculated any more and quit Axillary temperature ≥37℃ before immunization Reasons that can not conduct inoculation, in the judgment of investigators.

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 36 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Influenza Split Vaccine<br>7.5μg HA/strain/0.25ml/syringe | Biological: Influenza Split Vaccine<br>* 0.25ml, two doses (540 subjects were randomly assigned to receive the first dose, among them, 515 subjects received a boost dose); two doses were assigned to be vaccinated 4 weeks apart<br>* Other names: Hualan Biologicals;|
| Active Comparator: Inactivated Influenza Vaccine<br>7.5μg HA/strain/0.25ml/syringe | Biological: Inactivated Influenza Vaccine<br>* 0.25ml, two doses (270 subjects were randomly assigned to receive the first dose; among them, 263 subjects received a boost dose); two doses was administrated at 4 weeks apart<br>* Other names: Vaxigrip, Shenzhen Aventis Pasteur Biological;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects with adverse reactions as a measure of safety study | Local reactions, systemic reactions, severity degree and AEFI correlation | 28 days after the vaccination | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Observation of the immunogenicity | HI antibody seroconversion ratios, protection ratios, GMTs and GMT increase folds | 28 days after the immunization | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pediatric influenza vaccine